不同剂量利伐沙班与华法林对高龄非瓣膜性心房颤动患者的抗凝治疗效果及安全性比较

Abstract
Figure/Table
References (15)
Related Citation (15)

Download: PDF (0 KB) HTML (36 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective To explore the effect and safety of anticoagulant therapy of different doses of Rivaroxaban and Warfarin in the treatment of elderly patients with non-valvular atrial fibrillation. Methods A total of 120 elderly patients with non-valvular atrial fibrillation treated in Wuhan No.7 Hospital from April 2015 to April 2019 were selected as the research objects. They were divided into the low-dose Rivaroxaban group (30 cases), the regular-dose Rivaroxaban group (30 cases), the high-dose Rivaroxaban group (30 cases), and the Warfarin group (30 cases) by random number table method. Patients in the low-dose Rivaroxaban group were treated with 5 mg Rivaroxaban, those in the regulardose Rivaroxaban group were treated with 10 mg Rivaroxaban, those in the high-dose Rivaroxaban group were treated with 20 mg Rivaroxaban, and those in the Warfarin group were treated with Warfarin. The coagulation function, thromboembolic events, bleeding events and adverse reactions of the four groups were compared. Results Comparison of coagulation function indexes before treatment among the four groups showed no statistically significant differences (P>0.05). Comparison of coagulation function indexes after treatment among the four groups showed no statistically significant differences (P>0.05). The prothrombin time (PT) of the four groups after treatment was longer than that before treatment, and the antithrombin Ⅲwas higher than that before treatment, with statistically significant differences (P<0.05). D-dimer levels after treatment in the four groups were lower than those before treatment, and the differences were statistically significant (P<0.05). Comparison of the total incidence of thromboembolic events among the four groups showed no statistically significant differences (P>0.05). Comparison of the total incidence of bleeding events among the four groups showed no statistically significant differences (P>0.05). The total incidence rates of adverse reactions in the four groups were compared, and the differences were not statistically significant (P>0.05). Conclusion Rivaroxaban at different doses and Warfarin are equally effective and safe in anticoagulation therapy for elderly patients with non-valvular atrial fibrillation. In view of the limitations of Warfarin therapy, low-dose Rivaroxaban should be the first choice for anticoagulation therapy in elderly patients with non-valvular atrial fibrillation.

Key words： Different doses Rivaroxaban Warfarin Elderly Non-valvular atrial fibrillation Anticoagulant therapy;Safety

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	WU Xuan
	XU Xue-qing
	WANG Jia-shu
	WANG Kun

Cite this article:

WU Xuan,XU Xue-qing,WANG Jia-shu, et al. Effect and safety comparison of anticoagulant therapy of different doses of Rivaroxaban and Warfarin in elderly patients with non-valvular atrial fibrillation[J]. 中国当代医药, 2021, 28(3): 90-94.

URL:

http://dangdaiyiyao.com/EN/ OR http://dangdaiyiyao.com/EN/Y2021/V28/I3/90

[1]	邢宇，栗印军.利伐沙班、达比加群酯和华法林用于高龄非瓣膜性房颤病人抗凝治疗的有效性和安全性对比研究[J].中西医结合心脑血管病杂志，2019，17（3）：411-413.
[2]	梁春波，马瑾华，刘岩，等.利伐沙班、达比加群酯在高龄非瓣膜性心房颤动患者抗凝治疗中有效性与安全性研究[J].临床军医杂志，2018，46（5）：548-551.
[3]	赵瑞骅，李小明，马英，等.高龄老年非瓣膜性心房颤动患者应用新型口服抗凝药抗凝治疗有效性及安全性评价研究[J].中国药物与临床，2017，17（6）：805-809.
[4]	张清琼，孙学春，周晓芳，等.新型口服抗凝药物治疗高龄非瓣膜性房颤患者的疗效分析[J].重庆医学，2016，45（4）：486-489.
[5]	张申伟，袁义强.高龄非瓣膜性房颤患者应用利伐沙班与达比加群酯治疗的疗效及安全性分析[J].华夏医学，2019，32（4）：48-51.
[6]	武云涛，姚璐，田国祥，等.利伐沙班在高龄老年非瓣膜性房颤患者抗凝治疗的疗效及安全性[J].中国循证心血管医学杂志，2017，9（9）：1066-1068.
[7]	张静，侯丽萍，刘金苹，等.老年综合评估与干预对高龄非瓣膜性房颤抗凝率的影响[J].医学与哲学（B），2016，37（10）：37-40.
[8]	金鹏，周琪，石向明，等.利伐沙班和达比加群酯治疗高龄非瓣膜性房颤病人的安全性及疗效观察[J].中西医结合心脑血管病杂志，2016，14（13）：1504-1506.
[9]	赵宁宁，张亚娣，张盼盼.利伐沙班与华法林对房颤合并ACS 患者PCI 介入治疗后不良心血管事件的临床应用比较[J].辽宁医学杂志，2020，34（2）：33-35.
[10]	李支娣.新型口服抗凝药用于高龄非瓣膜性心房颤动患者抗凝治疗的有效性及安全性分析[J].中国基层医药，2020，27（7）：863-867.
[11]	祖武，刘冰，金春.对比利伐沙班与华法林治疗非瓣膜性心房颤动的临床疗效及对用药1年半后并发症的影响探究[J].当代医学，2020，26（8）：142-144.
[12]	白彦.利伐沙班与华法林对非瓣膜性心脏病房颤患者预防血栓栓塞的效果和出血风险评价[J].基层医学论坛，2020，24（7）：942-943.
[13]	陈海红，陆建辉.用利伐沙班、达比加群酯与华法林对非瓣膜性心房颤动患者进行抗凝治疗的效果比较[J].当代医药论丛，2019，17（22）：139-140.
[14]	张燕，王曙霞，马守原，等.老年非瓣膜性心房颤动患者服用利伐沙班的有效性及安全性研究[J].中国临床保健杂志，2019，22（5）：588-591.
[15]	陈丽，宫玉霞，张秀林.利伐沙班与华法林治疗高龄（≥80 岁）非瓣膜性心房颤动患者临床疗效的对比研究[J].实用心脑肺血管病杂志，2018，26（9）：63-66